JP2018507249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507249A5 JP2018507249A5 JP2017546913A JP2017546913A JP2018507249A5 JP 2018507249 A5 JP2018507249 A5 JP 2018507249A5 JP 2017546913 A JP2017546913 A JP 2017546913A JP 2017546913 A JP2017546913 A JP 2017546913A JP 2018507249 A5 JP2018507249 A5 JP 2018507249A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- group
- protein
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100030708 GTPase KRas Human genes 0.000 claims 12
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 8
- 102100039788 GTPase NRas Human genes 0.000 claims 6
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 102000016914 ras Proteins Human genes 0.000 claims 5
- 108010014186 ras Proteins Proteins 0.000 claims 5
- 102200006520 rs121913240 Human genes 0.000 claims 5
- 102200006525 rs121913240 Human genes 0.000 claims 5
- 102200007373 rs17851045 Human genes 0.000 claims 5
- 102200006648 rs28933406 Human genes 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 102200006657 rs104894228 Human genes 0.000 claims 4
- 102200006531 rs121913529 Human genes 0.000 claims 4
- 102200006538 rs121913530 Human genes 0.000 claims 4
- 102220197834 rs121913535 Human genes 0.000 claims 4
- 102200006593 rs727503093 Human genes 0.000 claims 4
- 102220306275 rs768029813 Human genes 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 102220197780 rs121434596 Human genes 0.000 claims 3
- 102220197831 rs121913527 Human genes 0.000 claims 3
- 102200006540 rs121913530 Human genes 0.000 claims 3
- 102200006533 rs121913535 Human genes 0.000 claims 3
- 102200006564 rs121917759 Human genes 0.000 claims 3
- 102220091421 rs876657848 Human genes 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 102220640055 Alpha-mannosidase 2_G12L_mutation Human genes 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 108091006097 G12 proteins Proteins 0.000 claims 2
- 102000056800 G12-G13 GTP-Binding Protein alpha Subunits Human genes 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102220530637 Putative apolipoprotein(a)-like protein 2_G12F_mutation Human genes 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102200006562 rs104894231 Human genes 0.000 claims 2
- 102220004443 rs104894360 Human genes 0.000 claims 2
- 102200006539 rs121913529 Human genes 0.000 claims 2
- 102220334606 rs1348427922 Human genes 0.000 claims 2
- 102220293980 rs143960528 Human genes 0.000 claims 2
- 102200007376 rs770248150 Human genes 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- -1 S17 Proteins 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 102220014333 rs112445441 Human genes 0.000 claims 1
- 102200158048 rs121913223 Human genes 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562129654P | 2015-03-06 | 2015-03-06 | |
| US62/129,654 | 2015-03-06 | ||
| US201562249788P | 2015-11-02 | 2015-11-02 | |
| US62/249,788 | 2015-11-02 | ||
| PCT/US2016/020390 WO2016144635A1 (en) | 2015-03-06 | 2016-03-02 | Method of treating cancer associated with a ras mutation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507249A JP2018507249A (ja) | 2018-03-15 |
| JP2018507249A5 true JP2018507249A5 (enExample) | 2019-04-11 |
| JP6769982B2 JP6769982B2 (ja) | 2020-10-14 |
Family
ID=56878960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546913A Active JP6769982B2 (ja) | 2015-03-06 | 2016-03-02 | Ｒａｓ変異と関連するがんの治療方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10238650B2 (enExample) |
| EP (1) | EP3265090A4 (enExample) |
| JP (1) | JP6769982B2 (enExample) |
| KR (1) | KR102626155B1 (enExample) |
| CN (1) | CN107530341B (enExample) |
| AU (2) | AU2016229294B2 (enExample) |
| BR (1) | BR112017018954A2 (enExample) |
| CA (1) | CA2978567A1 (enExample) |
| CL (1) | CL2017002241A1 (enExample) |
| HK (1) | HK1249052A1 (enExample) |
| IL (1) | IL254256A0 (enExample) |
| MX (1) | MX383691B (enExample) |
| MY (1) | MY190034A (enExample) |
| RU (1) | RU2736045C2 (enExample) |
| SG (2) | SG11201707127VA (enExample) |
| WO (1) | WO2016144635A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2736045C2 (ru) | 2015-03-06 | 2020-11-11 | Бейондспринг Фармасьютикалс, Инк. | Способ лечения рака, ассоциированного с мутацией ras |
| US10076518B2 (en) | 2015-03-06 | 2018-09-18 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
| CA2991059C (en) | 2015-07-13 | 2024-01-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin monohydrate polymorphs |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| US11229642B2 (en) | 2016-06-06 | 2022-01-25 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| MY201811A (en) | 2017-02-01 | 2024-03-19 | Beyondspring Pharmaceuticals Inc | Method of reducing neutropenia |
| JP2019019094A (ja) * | 2017-07-19 | 2019-02-07 | 学校法人福岡大学 | 変異ｋｒａｓ関連シグナル阻害用組成物 |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| AU2019212118A1 (en) * | 2018-01-24 | 2020-09-03 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| US11723891B2 (en) | 2018-04-12 | 2023-08-15 | Umc Utrecht Holding B.V. | Drug combinations for use in the treatment of RAS-mutant cancer |
| JP7500438B2 (ja) * | 2018-06-01 | 2024-06-17 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法 |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| CN109652535A (zh) * | 2019-01-30 | 2019-04-19 | 上海安甲生物科技有限公司 | 鉴别人甲状腺结节良恶性的试剂盒及其使用方法和应用 |
| KR102222693B1 (ko) * | 2019-04-04 | 2021-03-04 | 금정제약 주식회사 | H-rev107 유래 펩타이드의 신규한 용도 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| KR20220106980A (ko) | 2019-10-28 | 2022-08-01 | 머크 샤프 앤드 돔 코포레이션 | Kras g12c 돌연변이체의 소분자 억제제 |
| JP7668033B2 (ja) | 2019-11-28 | 2025-04-24 | ▲應▼世生物科技（南京）有限公司 | 癌の治療におけるｂｉ８５３５２０の使用 |
| WO2021106230A1 (ja) | 2019-11-29 | 2021-06-03 | 大鵬薬品工業株式会社 | 新規なフェノール化合物又はその塩 |
| CN111534599A (zh) * | 2020-06-18 | 2020-08-14 | 重庆浦洛通基因医学研究院有限公司 | 一种甲状腺癌辅助分子诊断试剂盒及使用方法 |
| JP2024513505A (ja) * | 2021-04-09 | 2024-03-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍を治療するための組成物及び方法 |
| CA3234699A1 (en) * | 2021-10-07 | 2023-04-13 | Beyondspring Pharmaceuticals, Inc. | Methods for treating cancers and tumors |
| CA3256645A1 (en) | 2022-05-06 | 2025-04-23 | Chugai Seiyaku Kabushiki Kaisha | CYCLIC COMPOUND HAVING A SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS |
| AU2023300980A1 (en) * | 2022-06-26 | 2025-01-09 | Biohaven Therapeutics Ltd. | Methods of treating glioblastoma with prodrugs of riluzole |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| CN117919235A (zh) * | 2022-10-25 | 2024-04-26 | 上海润石医药科技有限公司 | 一种萘酰胺化合物治疗kras突变相关疾病的用途 |
| WO2024088275A1 (zh) * | 2022-10-25 | 2024-05-02 | 中国科学院上海药物研究所 | 一种萘酰胺化合物治疗耐药性肿瘤的用途 |
| CN117942400A (zh) * | 2022-10-31 | 2024-04-30 | 四川大学 | Beclin 1抑制剂在制备治疗p53野生型癌症的药物中的用途 |
| EP4615847A1 (en) * | 2022-11-11 | 2025-09-17 | Merck Sharp & Dohme LLC | Small molecule inhibitors of kras proteins |
| WO2024249155A1 (en) * | 2023-06-02 | 2024-12-05 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS509164B1 (enExample) | 1970-12-29 | 1975-04-10 | ||
| KR850000073B1 (ko) | 1979-06-29 | 1985-02-18 | 더 웰컴 파운데이숀 리미티드 | 5-(2-포르밀-3-히드록시페녹시)펜타노익 산류의 제조방법 |
| IL64573A (en) | 1980-12-18 | 1985-04-30 | Wellcome Found | Derivatives of formylphenoxyalkanoic acids and formylphenoxymethylbenzoic acids,their preparation and pharmaceutical formulations containing them |
| JPS58167304A (ja) | 1982-03-24 | 1983-10-03 | 松下電器産業株式会社 | ごみ処理装置 |
| AU576322B2 (en) | 1983-07-22 | 1988-08-25 | Ici Australia Limited | Alpha-substituted-alpha-cyanomethyl alcohols |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| JPH05255106A (ja) | 1990-10-31 | 1993-10-05 | Toray Ind Inc | 血小板減少症治療剤 |
| JPH059164A (ja) | 1991-07-02 | 1993-01-19 | Sumitomo Chem Co Ltd | 光学活性マンデロニトリル誘導体の製造方法 |
| GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
| US6096786A (en) | 1992-10-01 | 2000-08-01 | Glaxo Wellcome Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
| US5872151A (en) | 1992-10-01 | 1999-02-16 | Glaxo Wellcome Inc. | Immunopotentiatory agents and physiologically acceptable salts thereof |
| DK0609606T3 (enExample) | 1992-10-01 | 1997-03-17 | Wellcome Found | |
| DK0674510T3 (da) | 1992-11-27 | 1999-05-10 | Napro Biotherapeutics Inc | Injicerbart præparat omfattende paclitaxel |
| JPH0725858A (ja) | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | ピペラジン誘導体 |
| US5958980A (en) | 1993-08-26 | 1999-09-28 | Glaxo Wellcome, Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
| IL110787A0 (en) | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
| GB9402809D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| JP3131574B2 (ja) | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤 |
| US5939098A (en) | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
| MXPA00004919A (es) | 1997-11-21 | 2002-10-17 | Euro Celtique Sa | 2-aminoacetamidas sustituidas y uso de las mismas. |
| BR9908207A (pt) | 1998-01-29 | 2000-11-28 | Aventis Pharm Prod Inc | Processo para preparar um composto de n- [ ( (alifático ou aromático) carbonil] -2-aminoacetamida, e, isonitrila ligada à resina |
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US6069146A (en) | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
| WO1999050245A1 (en) | 1998-03-26 | 1999-10-07 | Shionogi & Co., Ltd. | Indole derivatives with antiviral activity |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| GB9818627D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
| FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7026322B2 (en) | 1998-11-12 | 2006-04-11 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| US6358957B1 (en) | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| AU784062B2 (en) | 1999-08-23 | 2006-01-19 | Dana-Farber Cancer Institute, Inc. | Novel B7-4 molecules and uses therefor |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| EP3225632B1 (en) | 1999-11-30 | 2020-05-06 | Mayo Foundation for Medical Education and Research | Antibodies binding to b7-h1, a novel immunoregulatory molecule |
| AU782917C (en) | 2000-01-18 | 2006-11-23 | Beyondspring Pharmaceuticals, Inc. | Cell division inhibitors and process for producing the same |
| US6649172B2 (en) | 2000-03-17 | 2003-11-18 | Corixa Corporation | Amphipathic aldehydes and their uses as adjuvants and immunoeffectors |
| HUP0302358A3 (en) | 2000-05-09 | 2007-09-28 | Adpharma | Piperazinedione compounds and use of them for producing pharmaceutical compositions |
| JP2004518731A (ja) | 2000-12-28 | 2004-06-24 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | 三環式ｃｒｆレセプターアンタゴニスト |
| US20030082140A1 (en) * | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
| US20040176372A1 (en) | 2002-03-01 | 2004-09-09 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| AU2003244646B2 (en) | 2002-05-17 | 2008-08-07 | Aventis Pharma S.A. | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| US7064201B2 (en) | 2002-08-02 | 2006-06-20 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| WO2005077940A1 (en) * | 2004-02-04 | 2005-08-25 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| PL1740593T3 (pl) | 2004-04-19 | 2016-09-30 | Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I | |
| DE202004018940U1 (de) | 2004-12-07 | 2006-04-13 | Asf Verwaltungs Gmbh | Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| WO2007035841A1 (en) | 2005-09-21 | 2007-03-29 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| KR20080089489A (ko) | 2006-01-18 | 2008-10-06 | 메르크 파텐트 게엠베하 | 인테그린 리간드를 사용하는 암치료용 특이적 요법 |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| ES2527412T3 (es) | 2007-02-15 | 2015-01-23 | Mannkind Corporation | Método para aumentar la respuesta de los linfocitos T |
| JP5641927B2 (ja) | 2007-04-13 | 2014-12-17 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Ｓｐａｒｃ及びその使用方法 |
| US20090170837A1 (en) * | 2007-08-17 | 2009-07-02 | Thallion Pharmaceuticals Inc. | Methods for treating ras driven cancer in a subject |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| KR20100100949A (ko) | 2008-01-08 | 2010-09-15 | 브리스톨-마이어스 스큅 컴퍼니 | 증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| EP2387420A2 (en) | 2009-01-16 | 2011-11-23 | Teva Pharmaceutical Industries Limited | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein |
| WO2010114922A1 (en) | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| PL2464218T3 (pl) | 2009-08-10 | 2015-12-31 | Univ Texas | Leczenie przerzutów do mózgu z zastosowaniem inhibitorów receptorów endoteliny w skojarzeniu z cytotoksycznym środkiem chemioterapeutycznym |
| US20110160159A1 (en) | 2009-09-15 | 2011-06-30 | John Ryan | Treatment of cancer |
| MX2012004721A (es) | 2009-10-23 | 2012-06-25 | Mannkind Corp | Inmunoterapia de cancer y metodo de tratamiento. |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| CN101766815B (zh) | 2009-12-31 | 2012-04-25 | 胡松华 | 紫杉醇及多西紫杉醇的用途 |
| EP2542699A4 (en) * | 2010-03-03 | 2013-10-02 | Targeted Molecular Diagnostics Llc | METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION |
| EP2571577A1 (en) | 2010-05-17 | 2013-03-27 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
| US20130131018A1 (en) | 2010-06-04 | 2013-05-23 | Exonhit S.A. | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| JP2012033526A (ja) | 2010-07-28 | 2012-02-16 | Fuji Electric Co Ltd | 薄膜太陽電池およびその製造方法 |
| WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| WO2012074904A2 (en) | 2010-11-29 | 2012-06-07 | Precision Therapeutics, Inc. | Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents |
| TWI386203B (zh) | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| CN104024851A (zh) | 2011-11-28 | 2014-09-03 | 加拿大国家研究委员会 | 针对癌症的紫杉醇反应标志物 |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| DK2846809T3 (da) | 2012-05-09 | 2021-01-18 | Cantex Pharmaceuticals Inc | Behandling af myelosuppression |
| AU2013204313C1 (en) | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
| WO2014066834A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| MX374929B (es) | 2013-02-20 | 2025-03-06 | Novartis Ag | RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO. |
| AU2014244083B2 (en) | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| EP2988668B1 (en) | 2013-04-24 | 2019-07-24 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Magnetic resonance maps for analyzing tissue |
| SG11201509742QA (en) | 2013-06-03 | 2015-12-30 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| US10596169B2 (en) | 2013-10-11 | 2020-03-24 | Beyondspring Inc. | Cancer treatment with combination of plinabulin and taxane |
| EP4461372A3 (en) | 2013-11-05 | 2025-01-22 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| EP3594359B1 (en) | 2013-11-06 | 2022-05-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Method for subtyping lymphoma types by means of expression profiling |
| CN104796448B (zh) | 2014-01-22 | 2019-02-12 | 腾讯科技（深圳）有限公司 | 网络系统的数据处理方法和装置 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| RU148945U1 (ru) | 2014-07-29 | 2014-12-20 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу) | Конвективный блок водогрейного котла |
| CN106794246B (zh) | 2014-08-08 | 2021-10-15 | OncoQuest制药有限公司 | 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能 |
| WO2016081281A1 (en) | 2014-11-17 | 2016-05-26 | Salk Institute For Biological Studies | Lipophilic bisphosphonates and methods of use |
| CA2975729A1 (en) | 2015-02-12 | 2016-08-18 | Beyondspring Pharmaceuticals, Inc. | Use of plinabulin in combination with immune checkpoint inhibitors |
| RU2736045C2 (ru) | 2015-03-06 | 2020-11-11 | Бейондспринг Фармасьютикалс, Инк. | Способ лечения рака, ассоциированного с мутацией ras |
| US10076518B2 (en) | 2015-03-06 | 2018-09-18 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
| WO2016165007A1 (en) | 2015-04-17 | 2016-10-20 | The University Of British Columbia | Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer |
| CN106279039B (zh) | 2015-06-02 | 2019-01-11 | 青岛海洋生物医药研究院股份有限公司 | 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用 |
| CA2991059C (en) | 2015-07-13 | 2024-01-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin monohydrate polymorphs |
| CA2996426A1 (en) | 2015-10-05 | 2017-04-13 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| US11229642B2 (en) | 2016-06-06 | 2022-01-25 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| MY201811A (en) | 2017-02-01 | 2024-03-19 | Beyondspring Pharmaceuticals Inc | Method of reducing neutropenia |
| JP7280192B2 (ja) | 2017-03-13 | 2023-05-23 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリン組成物及びその使用 |
| US10933061B2 (en) | 2017-12-21 | 2021-03-02 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate therapies and methods of use |
| AU2019212118A1 (en) | 2018-01-24 | 2020-09-03 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| CN112105363A (zh) | 2018-02-01 | 2020-12-18 | 大连万春布林医药有限公司 | 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法 |
| CN110240592A (zh) | 2018-03-08 | 2019-09-17 | 青岛海洋生物医药研究院股份有限公司 | (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用 |
| CA3095709A1 (en) | 2018-04-05 | 2019-10-10 | Noviga Research Ab | Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer |
| JP7500438B2 (ja) | 2018-06-01 | 2024-06-17 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法 |
| MX2021001762A (es) | 2018-08-16 | 2021-04-19 | Beyondspring Pharmaceuticals Inc | Metodo y composicion para estimular la respuesta inmunitaria. |
| CA3119768A1 (en) | 2018-11-14 | 2020-05-22 | Beyondspring Pharmaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
| CN112778155B (zh) | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
| EP4146216A4 (en) | 2020-05-04 | 2024-05-29 | Beyondspring Pharmaceuticals Inc. | TRITHERAPY TO IMPROVE THE DESTRUCTION OF CANCER CELLS IN LOW IMMUNOGENICITY CANCERS |
-
2016
- 2016-03-02 RU RU2017131430A patent/RU2736045C2/ru active
- 2016-03-02 HK HK18108934.2A patent/HK1249052A1/zh unknown
- 2016-03-02 WO PCT/US2016/020390 patent/WO2016144635A1/en not_active Ceased
- 2016-03-02 MX MX2017011374A patent/MX383691B/es unknown
- 2016-03-02 BR BR112017018954-2A patent/BR112017018954A2/pt not_active Application Discontinuation
- 2016-03-02 MY MYPI2017703252A patent/MY190034A/en unknown
- 2016-03-02 KR KR1020177028572A patent/KR102626155B1/ko active Active
- 2016-03-02 SG SG11201707127VA patent/SG11201707127VA/en unknown
- 2016-03-02 SG SG10202008673WA patent/SG10202008673WA/en unknown
- 2016-03-02 JP JP2017546913A patent/JP6769982B2/ja active Active
- 2016-03-02 AU AU2016229294A patent/AU2016229294B2/en active Active
- 2016-03-02 EP EP16762149.9A patent/EP3265090A4/en active Pending
- 2016-03-02 CN CN201680022546.4A patent/CN107530341B/zh active Active
- 2016-03-02 US US15/555,963 patent/US10238650B2/en active Active
- 2016-03-02 CA CA2978567A patent/CA2978567A1/en active Pending
-
2017
- 2017-08-31 IL IL254256A patent/IL254256A0/en unknown
- 2017-09-04 CL CL2017002241A patent/CL2017002241A1/es unknown
-
2019
- 2019-03-01 US US16/290,765 patent/US10668063B2/en active Active
-
2020
- 2020-06-01 US US16/889,251 patent/US11045467B2/en active Active
-
2021
- 2021-05-24 US US17/328,091 patent/US11918574B2/en active Active
- 2021-12-21 AU AU2021290270A patent/AU2021290270A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507249A5 (enExample) | ||
| RU2017131430A (ru) | Способ лечения рака, ассоциированного с мутацией ras | |
| IL263373B1 (en) | Genetically modified vaccinia virus, preparations containing it and its uses | |
| MA41937B1 (fr) | Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 | |
| JOP20190154B1 (ar) | بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم | |
| MX372942B (es) | Derivados de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-fluoro-4-[(3-oxo-4h-pirido[2,3 b]piracin-8-il)oxi]fenil]urea como inhibidores de raf para el tratamiento del cancer. | |
| WO2015048345A3 (en) | Compositions and formulations for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment | |
| JP2016533366A5 (enExample) | ||
| SA515370134B1 (ar) | تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي | |
| NZ724368A (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
| CN110545820A (zh) | 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用 | |
| EA201691053A1 (ru) | Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии | |
| WO2017189856A3 (en) | Compositions and methods for treating cancer | |
| Kong et al. | miR-1271 inhibits OSCC cell growth and metastasis by targeting ALK | |
| MX2019003546A (es) | Virus oncoliticos optimizados y usos de los mismos. | |
| NZ596861A (en) | Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer | |
| WO2018085551A3 (en) | Formulations of pegylated arginine deiminase | |
| WO2014166084A8 (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
| EP3362452A4 (en) | THERAPEUTIC TARGETING OF CASEINKINASE-1 IN BREAST CANCER | |
| WO2016168150A3 (en) | Treatment for cancer metastasis | |
| WO2016191703A3 (en) | Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer | |
| Taneja | Re: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | |
| 金时代 et al. | Intratumoral Microvessel Density as a Predictor of Bevacizumab Therapeutic Efficiency in Metastatic Colorectal Cancer Patients | |
| Min | Realities of KRAS-mutated non-small cell lung cancer |